Citigroup’s Arcus Biosciences RCUS Stock Holding History

Citigroup’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$542K	Buy	+21,000	New	+$592K	﹤0.01%	3719
2026 Q2	–	Sell	-30,000	Closed	-$648K	–	6159
2026 Q1	$648K	Hold	30,000	–	–	﹤0.01%	3389
2025 Q4	$715K	Buy	30,000 +200	+0.7%	+$4.08K	﹤0.01%	3361
2025 Q3	$405K	Hold	29,800	–	–	﹤0.01%	3678
2025 Q2	$243K	Sell	29,800 -29,900	-50%	-$255K	﹤0.01%	3975
2025 Q1	$469K	Buy	59,700 +29,800	+100%	+$345K	﹤0.01%	3718
2024 Q4	$445K	Buy	+29,900	New	+$488K	﹤0.01%	3913
2023 Q1	–	Sell	-20,000	Closed	-$414K	–	5796
2022 Q4	$414K	Buy	20,000 +2,000	+11%	+$55K	﹤0.01%	3306
2022 Q3	$471K	Buy	18,000 +12,200	+210%	+$323K	﹤0.01%	3272
2022 Q2	$147K	Sell	5,800 -1,700	-23%	-$41.6K	﹤0.01%	4014
2022 Q1	$237K	Buy	+7,500	New	+$251K	﹤0.01%	3989
2021 Q4	–	Sell	-50,500	Closed	-$1.76M	–	6049
2021 Q3	$1.76M	Buy	+50,500	New	+$1.57M	﹤0.01%	2634

Other funds holding RCUS

Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Citigroup's RCUS Position: Q3 2026 in Review

Citigroup reduced its Arcus Biosciences (RCUS) stake by 50% in Q3 2026, selling an estimated $1.58M and leaving 56,268 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

Citigroup first reported a position in RCUS in Q1 2018 and has held it in 35 quarters since. The position peaked at $6.42M in Q1 2023. 137 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

Citigroup held 56,268 shares of Arcus Biosciences worth $1.45M as of Q3 2026.
Citigroup sold 55,970 Arcus Biosciences shares in Q3 2026, an estimated $1.58M.
Arcus Biosciences made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3055 holding.
Citigroup first reported a position in Arcus Biosciences in Q1 2018 and has held it in 35 quarters since.
Citigroup's Arcus Biosciences position peaked at $6.42M in Q1 2023.
137 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.